期刊
SEMINARS IN LIVER DISEASE
卷 37, 期 2, 页码 109-118出版社
THIEME MEDICAL PUBL INC
DOI: 10.1055/s-0037-1601349
关键词
hepatitis C; hepatocellular carcinoma; direct antiviral agents; incidence; recurrence
资金
- Instituto de Salud Carlos III [PI15/00145, PI15/00151, PI14/00962]
- AECC [PI044031]
- WCR (AICR) [16-0026]
- Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement [2014 SGR 605, 2014 SGR 233]
- Spanish Health Ministry (Plan Estrategico Nacional contra la Hepatitis C)
The availability of new direct antiviral agents to safely and effectively treat the hepatitis C virus represents a major advancement in the field of liver disease. Most patients achieve complete viral eradication sustained over time. In addition, the administration of these new agents is safe and does not require limitations when liver function is impaired. Some now expect the hepatitis C virus to be completely eradicated in a few years. However, not all data are positive. In April 2016, we published a cohort study suggesting that viral eradication with the new agents could be associated in time with the emergence of recurrent cancer sites in patients previously treated for hepatocellular carcinoma. In this review, we update our report and summarize the data provided in recent publications. We also speculate about themechanisms for cancer emergence and stress the need for further studies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据